CUP.F - Chugai Pharmaceutical Co., Ltd.

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Chugai Pharmaceutical Co., Ltd.

Nihonbashi Mitsui Tower
15th Floor 2-1-1 Nihonbashi-Muromachi Chuo-ku
Tokyo 103-8324
Japan
81 3 3281 6611
http://www.chugai-pharm.co.jp

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees7,432

Key Executives

NameTitlePayExercisedYear Born
Mr. Osamu NagayamaChairmanN/AN/A1947
Mr. Tatsuro KosakaPres, CEO & Representative DirectorN/AN/A1953
Mr. Motoo UenoDeputy ChairmanN/AN/AN/A
Mr. Toshiaki ItagakiEVP, CFO and GM of Fin. Supervisory Division, Fin. & Accounting Dept.N/AN/AN/A
Mr. Junichi EbiharaSr. VP & GM of Legal DepartmentN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Akynzeo, and Aloxi; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, Bonviva, and Alfarol; renal diseases consist of Mircera, Oxarol and Epogin; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, Pegasys, Sigmart, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd.; and collaborative research agreement with Anaeropharma Science Inc. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding AG.

Corporate Governance

Chugai Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of July 29, 2019 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.